AIP
KRTX

Almanack Investment Partners’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Almanack Investment Partners’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-226
Closed -$51K – 839
2022
Q3 		$51K Buy
+226
New +$45.7K 0.01% 262

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Almanack Investment Partners's KRTX Position: Q4 2022 in Review

Almanack Investment Partners sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q4 2022, closing a stake of 226 shares — an estimated $51K sold.

Almanack Investment Partners first reported a position in KRTX in Q3 2022 and held it in 1 quarter. The position peaked at $51K in Q3 2022. 248 funds tracked by Wall St. Rank hold KRTX as of Q4 2022.

  • Almanack Investment Partners reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Almanack Investment Partners sold 226 Karuna Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $51K.
  • Almanack Investment Partners first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Almanack Investment Partners's Karuna Therapeutics, Inc. Common Stock position peaked at $51K in Q3 2022.
  • 248 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Almanack Investment Partners's 13F filing for Q4 2022, filed 9 Feb 2023.